United States Patent 6,992,110: Milnacipran Pain-Treatment Claims, Scope, Expiration, and Patent Landscape

U.S. Patent No. 6,992,110 protects methods of treating pain with milnacipran, including use in humans, daily doses of approximately 25 to 400 mg, combination therapy with specified drug classes or named agents, and sustained-release formulations. The patent issued January 31, 2006. Its enforceable term has expired, subject to any applicable patent-term adjustment or disclaimer shown in the USPTO record. The claims are method-of-use claims, not composition-of-matter claims, and they do not independently protect milnacipran, its basic chemical structure, or every pharmaceutical formulation containing it.

What does U.S. Patent 6,992,110 protect?

The patent covers administering milnacipran, or a pharmaceutically acceptable salt, to an animal subject suffering from pain. Claim 1 is the central independent claim. Claims 2 through 6 narrow that method by adding combination therapies, human use, dosage, and sustained-release formulation limitations.

Claim	Subject matter	Claim type	Practical scope
1	Milnacipran for treating pain, alone or with a non-amino-acid adjunct	Independent method claim	Broadest claim
2	Adjunctive treatment with specified therapeutic classes	Dependent method claim	Covers combination therapy by class
3	Adjunctive treatment with named drugs	Dependent method claim	Covers listed combinations
4	Treatment of a human subject	Dependent method claim	Narrows claim 1 to humans
5	Approximately 25-400 mg per day	Dependent method claim	Dose-limited claim
6	Sustained-release dosage formulation	Dependent method claim	Formulation-limited method

The operative infringement theory requires more than the manufacture or sale of milnacipran. A claim requires use of milnacipran in treating pain, or conduct that induces or contributes to that use under applicable patent law.

What is the scope of claim 1?

Claim 1 has four principal elements:

An animal subject.
The subject is suffering from pain.
An effective amount of milnacipran, or a pharmaceutically acceptable salt, is administered.
The drug is administered alone or with a compound other than phenylalanine, tyrosine, or tryptophan.

The claim is broad in several respects. It does not limit pain to a particular disease, anatomical site, mechanism, duration, or severity. It does not require neuropathic pain, fibromyalgia, musculoskeletal pain, diabetic neuropathy, migraine, postoperative pain, or any other named indication. It also does not specify a particular route of administration, dosage form, dosing frequency, or salt.

The claim is narrower than a composition claim because the accused product must be used for the claimed therapeutic purpose. A generic milnacipran product with a label limited to a non-pain indication would present a different infringement analysis from a product labeled for pain treatment.

How does the combination language affect claim 1?

The phrase "alone or in combination" makes combination therapy optional. A method using milnacipran alone can satisfy claim 1. A method using milnacipran with another compound can also satisfy the claim, provided the additional compound is not one of the three excluded amino acids.

The exclusion of phenylalanine, tyrosine, and tryptophan is unusual. It appears designed to distinguish the claimed method from specific combinations involving those amino acids. It does not exclude ordinary analgesics, antidepressants, anticonvulsants, sedatives, muscle relaxants, or other co-administered drugs.

The exclusion is not a general limitation to approved co-medications. It is a chemical exclusion. A combination with morphine, tramadol, pregabalin, or a tricyclic antidepressant remains within the literal scope of claim 1 if the other claim elements are met.

What do claims 2 and 3 cover?

Claims 2 and 3 address adjunctive treatment.

Claim 2 covers milnacipran used with a compound in one of the following categories:

Antidepressants
Analgesics
Muscle relaxants
Anorectics
Stimulants
Antiepileptic drugs
Sedatives
Hypnotics

Claim 3 narrows the combination to named compounds or compound classes, including:

Neurontin, the brand name for gabapentin
Pregabalin
Pramipexole
1-DOPA, generally referring to levodopa
Amphetamine
Tizanidine
Clonidine
Tramadol
Morphine
A tricyclic antidepressant
Codeine
Carbamazepine
Sibutramine
Valium, the brand name for diazepam
Trazodone

The claims do not require a particular ratio, sequence, dosage schedule, pharmacological interaction, or clinical superiority from the combination. They require adjunctive administration, meaning the additional agent is used alongside milnacipran in the treatment regimen.

The named-drug claim may raise product-label and induced-infringement issues. A generic label that expressly recommends milnacipran with one of the named agents would create greater exposure than a label that omits the patented use. Medical practice alone, without a qualifying act by the manufacturer or another legally responsible party, is analyzed under the relevant direct or induced-infringement standards.

What pain indications are covered by U.S. Patent 6,992,110?

The claim language does not limit treatment to fibromyalgia. It covers pain generally, subject to the requirements of an effective amount and a subject suffering from pain.

Potentially relevant pain categories include:

Neuropathic pain
Chronic widespread pain
Fibromyalgia-associated pain
Musculoskeletal pain
Central pain
Inflammatory pain
Postoperative pain
Low-back pain
Pain associated with neurological disorders

The patent’s written description and prosecution history may affect how broadly "pain" and "effective amount" are construed. Claim construction would also consider the specification, prosecution amendments, examiner arguments, and any terminal disclaimer or priority relationship with related patents.

The practical value of the claims was strongest when milnacipran had no approved U.S. pain indication or when a listed product relied on pain-related labeling. After expiration, the claims no longer create an enforceable U.S. barrier.

Does claim 4 limit protection to humans?

Yes. Claim 4 narrows claim 1 to a human subject. Claim 1 itself covers an "animal subject," which ordinarily includes humans unless the specification or prosecution history indicates a narrower construction.

Claim 4 does not add a particular pain condition, dosage, route, or formulation. It is a subject-matter limitation. A human-use product can fall within claim 4 when the treatment otherwise satisfies claim 1.

What dosage range is protected by claim 5?

Claim 5 covers administration of approximately 25 mg to approximately 400 mg per day.

The range is broad and includes many potential clinical regimens. It does not specify:

Once-daily or divided dosing
Immediate-release or extended-release administration
A particular salt
A loading dose
Treatment duration
A specific therapeutic indication

The terms "about" and "approximately" ordinarily introduce some latitude around the numerical endpoints. The exact boundaries depend on claim construction and the specification. A regimen materially outside the range may avoid literal infringement of claim 5, but it could still fall within claim 1 or another claim if the remaining elements are satisfied.

What formulations are protected by claim 6?

Claim 6 covers the claimed pain-treatment method when the compound is formulated in a sustained-release dosage formulation.

The claim does not identify a particular:

Polymer
Matrix system
Coating
Osmotic system
Multiparticulate technology
Release profile
Tablet or capsule design
Milnacipran salt

Claim 6 is therefore a use claim with a formulation limitation. It does not, standing alone, claim every sustained-release milnacipran composition as a product. A formulation patent with detailed excipient or release-profile limitations would provide a different and potentially narrower form of protection.

A sustained-release product used for a non-pain indication would not automatically satisfy claim 6 because the treatment must still be directed to a subject suffering from pain.

When did U.S. Patent 6,992,110 expire?

U.S. Patent 6,992,110 issued on January 31, 2006. The patent belongs to the post-June 8, 1995 U.S. patent-term regime, under which the term generally runs 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimer, and other statutory modifications.[1]

Public patent records identify the patent as part of the milnacipran pain-treatment patent family associated with Cypress Bioscience and related rights holders. The patent’s ordinary term ran into 2020. The patent is no longer an active enforceable barrier in the United States.

Event	Date or status
Patent issued	January 31, 2006
Patent type	Utility patent
Technology	Milnacipran treatment of pain
Primary protection	Method of treatment
Expected ordinary term	Approximately 20 years from applicable earliest nonprovisional filing
Current status	Expired
Remaining enforceability	None, absent an unusual surviving statutory extension, which is not reflected in the ordinary patent record

The key commercial point is that current generic entry is not blocked by U.S. Patent 6,992,110. Historical Orange Book listing or prior Paragraph IV activity does not revive an expired patent.

What was the FDA and Orange Book status of milnacipran?

The FDA approved Savella, containing milnacipran hydrochloride, for the management of fibromyalgia in adults on January 14, 2009.[2] Savella was marketed in the United States by Forest Laboratories, later associated with Actavis and Allergan following corporate transactions.

Milnacipran is a small-molecule serotonin-norepinephrine reuptake inhibitor. Unlike duloxetine and some other agents in the class, its U.S. commercial positioning centered on fibromyalgia rather than major depressive disorder.

The Orange Book historically listed patents associated with Savella and milnacipran-related use protection. The existence of a historical listing is distinct from present enforceability. The FDA Orange Book identifies approved drug products, patents submitted by sponsors, and applicable exclusivity information. It does not determine final patent validity or infringement.[3]

What regulatory exclusivity applied?

Savella received U.S. approval in 2009. Any new-chemical-entity exclusivity associated with the approval would have run separately from patent protection and generally expired before the relevant patent term ended. The 2009 approval also created a regulatory approval pathway for generic applicants after statutory exclusivity and patent barriers were addressed.

Milnacipran is not a biologic. Biosimilar law under the Biologics Price Competition and Innovation Act does not apply. Generic applicants use the Abbreviated New Drug Application pathway, subject to bioequivalence, labeling, manufacturing, and patent-certification requirements.[4]

Were there Paragraph IV challenges to U.S. Patent 6,992,110?

A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. The certification can trigger patent litigation if the branded sponsor or patent owner files suit within the statutory period.

The patent’s relevance to generic applicants would have been highest before its 2020 expiration. A generic applicant could have challenged the patent through:

A Paragraph IV certification
A declaratory-judgment action
An inter partes review, where available
A district-court invalidity or noninfringement defense
A label-based carve-out strategy under section viii

The claim type created several potential challenge positions:

Challenge theory	Potential argument
Anticipation	Earlier disclosure of milnacipran for pain
Obviousness	Combining known SNRI pharmacology with established pain treatment
Written description	Broad coverage of all pain conditions or combinations
Enablement	Whether the full breadth of the claims was enabled
Indefiniteness	Scope of "effective amount," "about," and "sustained release"
Noninfringement	Product label omits pain use or claimed combination
Regulatory carve-out	Omission of a protected indication from the generic label

The record for a particular Paragraph IV case, settlement, or launch date must be assessed from FDA ANDA records, district-court dockets, and the Orange Book patent-history record. Patent 6,992,110 itself is expired, so a current Paragraph IV challenge to this patent would have no practical blocking effect.

What litigation affected the milnacipran patent estate?

The relevant litigation question is broader than Patent 6,992,110. Savella’s commercial protection could have depended on multiple patents, regulatory exclusivity, label strategy, and related patent-family rights.

A patent litigation review should distinguish:

Cases naming U.S. Patent 6,992,110.
Cases involving related milnacipran patents.
ANDA litigation concerning Savella.
Declaratory-judgment proceedings.
Inter partes review or post-grant proceedings.
Settlement agreements that delayed generic launch.
Cases dismissed after patent expiration or product discontinuation.

An expired patent can remain relevant historically in damages, settlement, and launch analysis, but it cannot support prospective injunctive relief after expiration. Any settlement that postponed generic entry beyond the patent’s expiration would require separate antitrust and commercial analysis.

How strong was the patent estate for milnacipran pain treatment?

The patent estate was moderate for historical use protection but weak as a long-term exclusivity platform.

Strengths

Claim 1 covered pain broadly.
The claim covered milnacipran alone, avoiding dependence on a combination product.
The patent did not require fibromyalgia specifically.
The dose range in claim 5 covered a wide range of clinical administration.
Claim 6 addressed sustained-release use.
Method-of-use protection could support label-based enforcement against a generic product promoting pain treatment.

Weaknesses

The patent did not claim milnacipran composition of matter.
The active ingredient was known before the U.S. pain-use patent.
Generic manufacturers could contest the novelty or obviousness of using milnacipran for pain.
The broad "animal subject" and "pain" language could create written-description, enablement, or construction disputes.
Combination claims depended on proof of adjunctive use.
A generic applicant could seek a label that omitted the patented use.
The patent term ended before long-term commercial erosion could be avoided through later patent protection.

The strongest commercial protection would have come from a valid composition-of-matter patent or a narrowly drafted, clinically supported indication patent with later expiration. Patent 6,992,110 instead provided use-based protection that was vulnerable to label design and ordinary validity challenges.

How does the patent compare with composition and formulation patents?

Protection type	What it protects	Relevance to milnacipran
Composition of matter	Active molecule or novel chemical entity	Broadest product protection; generally unavailable if the molecule was already known
Method of treatment	Use of milnacipran for pain	Core protection in Patent 6,992,110
Method of use for fibromyalgia	Use for a defined disease	More specific than claim 1, potentially easier to practice-label
Formulation	Release system, salt, excipients, or dosage form	Could protect a product even after broad use claims expire
Manufacturing process	Synthesis, purification, crystallization, or salt formation	Creates manufacturing barriers but usually does not block all generic products
Regulatory exclusivity	FDA approval-based marketing protection	Time-limited and separate from patent rights

Claim 6 is not equivalent to a detailed formulation patent. It protects the treatment method when a sustained-release formulation is used. A separate formulation patent would typically recite physical and chemical characteristics of the dosage form.

What generic entry risks existed?

Before expiration, generic entry risks fell into four scenarios.

1. Full-label generic launch

A generic applicant could seek approval for all non-protected indications after patent and exclusivity barriers expired. This presented the highest direct exposure to the branded product.

2. Carved-out labeling

The applicant could omit a patented pain indication from the label under a section viii statement, provided the remaining labeling did not encourage the patented use. This strategy reduces, but does not eliminate, induced-infringement risk.

3. Paragraph IV challenge

The applicant could certify that Patent 6,992,110 was invalid, unenforceable, or not infringed. Litigation could delay approval or create a potential 180-day first-filer advantage under the Hatch-Waxman framework.

4. At-risk launch

After FDA approval but before final resolution of patent litigation, a generic company could launch at risk. This exposes the company to damages and injunctive litigation if the patent survives and is infringed. That scenario is no longer relevant to this expired patent except for historical damages claims.

What licensing and ownership issues affected the patent?

The commercial history of milnacipran involved multiple entities, including Pierre Fabre-related interests, Cypress Bioscience, Forest Laboratories, and later corporate successors. Patent ownership, development rights, FDA sponsorship, and commercial marketing rights were not necessarily held by the same entity.

For diligence, the following must be separated:

Original patent applicant and assignee
Recorded assignments at the USPTO
Licensee with U.S. development rights
NDA holder
Commercial marketer
Current owner of any related patent
Party responsible for Orange Book certifications
Party involved in any generic settlement

A license to commercialize Savella would not automatically transfer ownership of Patent 6,992,110. Conversely, patent ownership would not necessarily establish control over the FDA-approved product or the NDA.

What is the geographic coverage of U.S. Patent 6,992,110?

The patent provides protection only under U.S. law. It does not directly cover:

European milnacipran use
Canadian use
Japanese use
Manufacturing outside the United States
Importation into another country
Foreign formulations

Related international applications may have produced national patents with different claim scope and expiration dates. Foreign patent rights must be analyzed separately by jurisdiction because filing dates, prosecution history, patent-term rules, supplemental protection certificates, and local infringement standards differ.

What manufacturing and intellectual-property barriers remain?

Patent 6,992,110 does not impose a current manufacturing barrier because it is expired. Remaining commercial barriers may include:

Active pharmaceutical ingredient qualification
Salt-form selection
Impurity controls
Crystallinity and polymorph control
Sustained-release manufacturing
Bioequivalence for modified-release products
Stability data
FDA facility inspection
Controlled supply-chain qualification
Trademark and trade-dress restrictions
Confidential manufacturing know-how

These barriers are commercial and regulatory rather than enforceable exclusivity created by Patent 6,992,110.

What revenue exposure did the patent create?

The patent’s revenue exposure was tied primarily to the Savella franchise and any future pain indication using milnacipran. It did not protect all milnacipran revenue because it did not claim the molecule itself or every indication.

Revenue sensitivity depended on:

The share of prescriptions used for pain or fibromyalgia
Whether the generic label included or omitted pain-related use
The number of approved generic suppliers
Wholesale acquisition price reductions
Substitution rates
Formulation availability
Any surviving related patents
Payer coverage and formulary placement

After patent expiration, the principal risk shifted from patent litigation to ordinary generic substitution and price erosion.

Key Takeaways

U.S. Patent 6,992,110 is a method-of-treatment patent for using milnacipran to treat pain.
Claim 1 is broad because it covers pain generally and permits milnacipran monotherapy.
Claims 2 and 3 cover adjunctive use with specified drug classes and named agents.
Claim 4 limits the method to humans.
Claim 5 covers approximately 25 to 400 mg per day.
Claim 6 covers sustained-release milnacipran treatment, not every sustained-release composition as a product.
The patent does not claim milnacipran itself.
The patent issued January 31, 2006 and is expired.
Milnacipran is a small molecule, so generic competition proceeds through the ANDA pathway rather than biosimilar regulation.
Any current generic-entry analysis must focus on remaining patents, FDA labeling, formulation rights, manufacturing constraints, and commercial execution rather than Patent 6,992,110.

FAQs About U.S. Patent 6,992,110

Can a generic manufacturer sell milnacipran after Patent 6,992,110 expired?

Yes. The expired patent no longer blocks U.S. manufacture, approval, or sale. The generic must still satisfy FDA requirements and avoid any valid, unexpired patent covering the product, indication, formulation, or manufacturing process.

Does Patent 6,992,110 cover Savella tablets as a product?

No. The patent principally claims methods of treating pain with milnacipran. It does not function as a composition-of-matter claim covering every Savella tablet.

Does the patent cover milnacipran for depression?

Not based on the quoted claims. The claims require treatment of a subject suffering from pain. Treatment for depression without a pain-treatment purpose would not satisfy the quoted claim language.

Could claim 6 cover an extended-release generic capsule?

It could have applied historically if the product were a sustained-release milnacipran formulation used to treat pain and the other claim elements were met. The claim is expired and does not currently create an enforceable barrier.

Is a biosimilar application required for milnacipran?

No. Milnacipran is a small-molecule drug. A competing manufacturer ordinarily uses the ANDA pathway, not the biosimilar pathway.

References

United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term. https://www.uspto.gov/patents/laws/patent-term-adjustment
U.S. Food and Drug Administration. (2009, January 14). FDA approves Savella to manage fibromyalgia. https://www.fda.gov/
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
U.S. Food and Drug Administration. (n.d.). Abbreviated New Drug Application (ANDA). https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda
U.S. Patent No. 6,992,110. (2006). Milnacipran for the treatment of pain. United States Patent and Trademark Office.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	552856	⤷ Start Trial
Australia	2003268020	⤷ Start Trial
Canada	2467356	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,992,110

Summary for Patent: 6,992,110